MTOR inhibitor for the treatment of hepatocellular carcinoma

Digestive Diseases

Volumn 29, Issue 3, 2011, Pages 310-315

  Kudo, Masatoshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Evelorimus; Hepatocellular carcinoma; mTOR inhibitor; RAD001

Indexed keywords

ALPHA INTERFERON; AURORA A KINASE; EPIDERMAL GROWTH FACTOR; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1; INITIATION FACTOR 4E BINDING PROTEIN; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PROTEIN KINASE B; PROTEIN P53; RIBOSOME PROTEIN; RIDAFOROLIMUS; SORAFENIB; TEMSIROLIMUS; TUBERIN; VASCULOTROPIN;

ADVANCED CANCER; ANOREXIA; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CONFERENCE PAPER; DIARRHEA; DOWNSTREAM PROCESSING; DRUG WITHDRAWAL; FATIGUE; GENE EXPRESSION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MALAISE; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUROENDOCRINE TUMOR; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN SYNTHESIS; RASH; RNA TRANSLATION; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; THYROID CANCER; UMBILICAL VEIN ENDOTHELIAL CELL; VOMITING;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; TOR SERINE-THREONINE KINASES;

EID: 80051739631     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000327565     Document Type: Conference Paper

References (31)

1. Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. Cell 2006; 124: 471-484. (Pubitemid 43199434)
2. Bjornsti MA, Houghton PJ: The TOR pathway: A target for cancer therapy. Nat Rev Cancer 2004; 4: 335-348. (Pubitemid 38579480)
3. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH: RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994; 78: 35-43. (Pubitemid 24228298)
4. Schmelzle T, Hall MN: TOR, a central controller of cell growth. Cell 2000; 103: 253-262.
5. Shaw RJ, Cantley LC: Ras, PI3K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 424-430. (Pubitemid 44050136)
6. Pouyssegur J, Dayan F, Mazure NM: Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006; 441: 437-443. (Pubitemid 44050138)
7. Seufferlein T, Rozengurt E: Rapamycin inhibits constitutive p70S6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res 1996; 56: 3895-3897. (Pubitemid 26284735)
8. Rosenwald IB, Kaspar R, Rousseau D, Gehrke L, Leboulch P, Chen JJ, et al: Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. J Biol Chem 1995; 270: 21176-1180.
9. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB: In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000; 6: 880-886. (Pubitemid 30159344)
10. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, et al: Regulation of hypoxia-inducible factor 1 expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002; 22: 7004-7014.
11. Grewe M, Gansauge F, Schmid RM, Adler G, Seufferlein T: Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70S6K pathway in human pancreatic cancer cells. Cancer Res 1999; 59: 3581-3587. (Pubitemid 29381856)
12. Abraham RT, Gibbons JJ: The mammalian target of rapamycin signaling pathway: Twists and turns in the road to cancer therapy. Clin Cancer Res 2007; 13: 3109-3114. (Pubitemid 46944891)
13. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135. (Pubitemid 34155123)
14. Yu Y, Sato JD: MAP kinases, phosphatidylinositol 3-kinase, and p70S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiol 1999; 178: 235-246. (Pubitemid 29034867)
15. Suhara T, Mano T, Oliveira BE, Walsh K: Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fasmediated apoptosis via regulation of FLICEinhibitory protein (FLIP). Circ Res 2001; 89: 13-19. (Pubitemid 34135486)
16. Bruns CJ, Koehl GE, Guba M, Yezhelyev M, Steinbauer M, Seeliger H, et al: Rapamycininduced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res 2004; 10: 2109-2119. (Pubitemid 38375573)
17. Huang S, Houghton PJ: Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003; 3: 371-377. (Pubitemid 36908940)
18. Baselga J, van Dam PA, Greil R, et al: Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER + breast cancer. J Clin Oncol 2008; 26 (ASCO 2008, abstr 530).
19. Muro K, Boku N, Yamada Y, et al: Multicenter phase II study of RAD001 for previously treated metastatic gastric cancer; preliminary results. J Clin Oncol 2008; 26 (ASCO 2008, abstr 4541).
20. Jac J, Giessinger S, Khan M, et al: A phase II trial of RAD001 in patients with metastatic renal cell carcinoma. J Clin Oncol 2007; 25(suppl 18):5107.
21. Motzer RJ, Escudier B, Oudard S, et al: RAD001 vs. placebo in patients with metastatic renal cell carcinoma after progression on VEGFr-TKI therapy; results from a randomized, double-blind, multicenter phase-III study. J Clin Oncol 2008; 26 (ASCO 2008, abstr LBA5026).
22. Boulay A, Lane HA: The mammalian target of rapamycin kinase and tumor growth inhibition. Recent Results Cancer Res 2007; 172: 99-124.
23. Shinohara ET, Cao C, Niermann K, Mu Y, Zeng F, Hallahan DE, et al: Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 2005; 24: 5414-5422. (Pubitemid 43080085)
24. Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, et al: RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007; 13: 4261-4270. (Pubitemid 47105991)
25. Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, et al: RAD001 (everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 2007; 67: 2408-2413. (Pubitemid 46548923)
26. Manegold PC, Paringer C, Kulka U, Krimmel K, Eichhorn ME, Wilkowski R, et al: Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res 2008; 14: 892-900. (Pubitemid 351231174)
27. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M: MTOR and p70S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004; 10: 8421-8425. (Pubitemid 40053405)
28. Schumacher G, Oidtmann M, Rueggeberg A, Jacob D, Jonas S, Langrehr JM, et al: Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 2005; 11: 1420-1425. (Pubitemid 40468074)
29. Semela D, Piguet AC, Kolev M, Schmitter K, Hlushchuk R, Djonov V, et al: Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 2007; 46: 840-848. (Pubitemid 46529039)
30. Sieghart W, Fuereder T, Schmid K, Cejka D, Werzowa J, Wrba F, et al: Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 2007; 83: 425-432. (Pubitemid 46667846)
31. Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, et al: Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer DOI: 10.1002/ cncr.26165.